Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Bisphosphonates are nonbiodegradable pyrophosphate analogues that are being used increasingly to inhibit bone resorption in disorders characterized by excessive bone loss. We have previously found that dichloromethylene bisphosphonate (Cl2MBP) inhibits bone resorption through injury to the cells that resorb Cl2MBP-contaminated surfaces. 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (AHPrBP) is a more potent inhibitor of bone resorption in vivo, and we have attempted to identify a step in the resorptive pathway that accounts for this increased potency. We found that when osteoclasts, isolated from neonatal rat long bones, were incubated on bone slices in the presence of bisphosphonates, AHPrBP was less, rather than more potent as a resorption-inhibitor than Cl2MBP. The greater sensitivity of resorption to AHPrBP in vivo could neither be attributed to an effect of AHPrBP on the ability of osteoblastic cells to stimulate resorption in response to calcium-regulating hormones in vitro nor to an effect on osteoclast generation: osteoclast formation was unaffected by concentrations of AHPrBP 10-fold higher than those of Cl2MBP which inhibit bone resorption in the bone slice assay. We also found no evidence for impaired osteoclast generation in vivo in AHPrBP-treated rats. These results suggest that the comparisons of potency in vitro do not include all the factors responsible for determining bisphosphonate potency in vivo. Because bisphosphonates owe the specificity of their actio…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This phenomenon is consistent with previous observations that bisphosphonates suppress bone resorption via injury to osteoclasts when they solubilize bisphosphonate-contaminated bone (139, 140).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [139]
Citations
Cites
Calcitonin alters behaviour of isolated osteoclasts
Chambers, T. J., & Magnus, C. J. (1982) · The Journal of Pathology · doi:10.1002/path.1711360104 · Cited by 504 · cited 1×
“Osteoclasts were isolated from neonatal rat long bones as previously described [28].”
MethodSelf-citationSchenk, R., Merz, W. A., Mühlbauer, R., Russell, R. G. G., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547219 · Cited by 482
Osteoblastic Cells Mediate Osteoclastic Responsiveness to Parathyroid Hormone*
McSHEEHY, P. M. J., & CHAMBERS, T. J. (1986) · Endocrinology · doi:10.1210/endo-118-2-824 · Cited by 407 · cited 3×
“The number of resorption pits and the plan area of bone resorption were assessed as previously described [29].”
BackgroundMethodSelf-citationThe binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals
Jung, A., Bisaz, S., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547227 · Cited by 381 · cited 1×
“Bisphosphonates (PCPs) are nonbiodegradable analogues of pyrophosphate with a high binding affinity for hydroxyapatite crystals [1].”
BackgroundHughes, D. E., MacDonald, B. R., Russell, R. G., & Gowen, M. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114100 · Cited by 357 · cited 2×
“Other experimental models that test the function of mature osteoclasts have similarly failed to demonstrate increased potency for AHPrBP, and this has led to the suggestion that AHPrBP impairs osteoclast generation [25].”
BackgroundTwo modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Reid, I. R., Alexander, C. J., King, A. R., & Ibbertson, H. K. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92721-3 · Cited by 341
(1985) · De Gruyter eBooks · doi:10.1515/9783112330005 · Cited by 325
Carano, A., Teitelbaum, S. L., Konsek, J. D., Schlesinger, P. H., & Blair, H. C. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114459 · Cited by 314 · cited 1×
“[38] who, using chick osteoclasts, found that AHPrBP was more potent than C12MBP by an order of magnitude.”
Structure-activity relationships of various bisphosphonates
Shinoda, H., Adamek, G., Felix, R., Fleisch, H., Schenk, R., & Hagan, P. (1983) · Calcified Tissue International · doi:10.1007/bf02405012 · Cited by 306 · cited 2×
“The relative potency of 3-amino-l-hydroxypropyl idene- l , l -b isphosphonate (AHPrBP, formerly APD), as judged by inhibition of bone resorption in organ culture, does not correlate with the increased relative potency of AHPrBP in vivo [16].”
Background
Research works printed but not linked: 3
- Huaux JP, Devogelaer JP, Brasseu JP, Nagant de Deuxchaisnes C (1985) Effect of the diphosphonate APD on dual photon absorptiometry in involutional osteoporosis. In: Norman AW (ed) Vitamin D. A chemical, biochemical and clinical update. Walter de Gruyter, Berlin, pp 998–999
- Ende JJ (1978) Some effects of EHDP and Cl2MDP on the metabolism of isolated bone cells. Proc Kon Med Akad Wet C81:252–264
- Ende JJ, van Rooijen HJM (1979) Some effects of EHDP and Cl2MBP on enzyme activiyt and substrate utilisation by mouse calvaria in tissue culture. Proc Kon Med Akad Wet C. 82:55–63
Cited by
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040
Biochemical markers and skeletal metastases
Demers, L. M., Costa, L., & Lipton, A. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2919::aid-cncr7>3.0.co;2-z · Cited by 161
Cellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l · Cited by 977
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Hortobagyi, G. N., Theriault, R. L., Lipton, A., Porter, L., Blayney, D., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J. J., Knight, R. D., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2038 · Cited by 631
Theriault, R. L., Lipton, A., Hortobagyi, G. N., Leff, R., Glück, S., Stewart, J. F., Costello, S., Kennedy, I., Simeone, J., Seaman, J. J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.846 · Cited by 604
Frith, J. C., Mönkkönen, J., Blackburn, G. M., Russell, R. G. G., & Rogers, M. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.9.1358 · Cited by 437
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.
Sahni, M., Guenther, H. L., Fleisch, H., Collin, P., & Martin, T. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116422 · Cited by 412
Regulation of Osteoclast Function
Suda, T., Nakamura, I., Jimi, E., & Takahashi, N. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.6.869 · Cited by 408
Bisphosphonates: Preclinical Review
Green, J. R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-3 · Cited by 405
Dr. Coxon, F. P., Helfrich, M. H., Van't Hof, R., Sebti, S., Ralston, S. H., Hamilton, A., & Rogers, M. J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1467 · Cited by 361
Rogers, M. J., Watts, D. J., & Russell, R. G. G. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1652::aid-cncr15>3.0.co;2-z · Cited by 285
LeGrand, A., Fermor, B., Fink, C., Pisetsky, D. S., Weinberg, J. B., Vail, T. P., & Guilak, F. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200109)44:9<1998::aid-art348>3.0.co;2-t · Cited by 204
Frith, J. C., M�nkk�nen, J., Auriola, S., M�nkk�nen, H., & Rogers, M. J. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200109)44:9<2201::aid-art374>3.0.co;2-e · Cited by 268
Benford, H. L., Frith, J. C., Auriola, S., Mönkkönen, J., & Rogers, M. J. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26392-6 · Cited by 256
Comparison of the distribution of 3H-alendronate and 3H-Etidronate in rat and mouse bones
Masarachia, P., Weinreb, M., Balena, R., & Rodan, G. A. (1996) · Bone · doi:10.1016/8756-3282(96)00182-2 · Cited by 248
Molecular mechanisms of action of bisphosphonates
Rogers, M. J., Frith, J. C., Luckman, S. P., Coxon, F. P., Benford, H. L., M̈onkk̈onen, J., Auriola, S., Chilton, K. M., & Russell, R. G. G. (1999) · Bone · doi:10.1016/s8756-3282(99)00070-8 · Cited by 237
Corey, E., Brown, L. G., Quinn, J. E., Poot, M., Roudier, M. P., Higano, C. S., & Vessella, R. L. (2003) · PubMed · Cited by 227
Murakami, H., Takahashi, N., Sasaki, T., Udagawa, N., Tanaka, S., Nakamura, I., Zhang, D., Barbier, A., & Suda, T. (1995) · Bone · doi:10.1016/s8756-3282(95)00150-6 · Cited by 218
Pennanen, N., Lapinjoki, S., Urtti, A., & Mönkkönen, J. (1995) · Pharmaceutical Research · doi:10.1023/a:1016281608773 · Cited by 211
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim, A., Scher, N. S., Williams, G., Sridhara, R., Li, N., Chen, G., Leighton, J. C., Booth, B. P., Gobburu, J. V. S., Rahman, A., et al. (2003) · PubMed · Cited by 196
Derenne, S., Amiot, M., Barillé, S., Collette, M., Robillard, N., Berthaud, P., Harousseau, J.-L., & Bataille, R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.12.2048 · Cited by 195
Dr. Rogers, M. J., Chilton, K. M., Coxon, F. P., Lawry, J., Smith, M. O., Suri, S., & Russel, R. G. G. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111015 · Cited by 194
Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats
Patlas, N., Golomb, G., Yaffe, P., Pinto, T., Breuer, E., & Ornoy, A. (1999) · Teratology · doi:10.1002/(sici)1096-9926(199908)60:2<68::aid-tera10>3.0.co;2-h · Cited by 186
The antineoplastic role of bisphosphonates: from basic research to clinical evidence
Santini, D., Vespasiani Gentilucci, U., Vincenzi, B., Picardi, A., Vasaturo, F., La Cesa, A., Onori, N., Scarpa, S., & Tonini, G. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg401 · Cited by 171
Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures
Nishikawa, M., Akatsu, T., Katayama, Y., Yasutomo, Y., Kado, S., Kugai, N., Yamamoto, M., & Nagata, N. (1996) · Bone · doi:10.1016/8756-3282(95)00426-2 · Cited by 161
Falls, Fractures, and Osteoporosis After Stroke: Time to Think About Protection?
Poole, K. E. S., Reeve, J., & Warburton, E. A. (2002) · Stroke · doi:10.1161/01.str.0000014510.48897.7d · Cited by 158
Azuma, Y., Sato, H., Oue, Y., OKABE, K., Ohta, T., Tsuchimoto, M., & Kiyoki, M. (1995) · Bone · doi:10.1016/8756-3282(94)00035-x · Cited by 157
Chemotherapy-Induced Ovarian Failure: Manifestations and Management
Molina, J. R., Barton, D. L., & Loprinzi, C. L. (2005) · Drug Safety · doi:10.2165/00002018-200528050-00004 · Cited by 148
Mundy, G. R., Yoneda, T., & Hiraga, T. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90263-5 · Cited by 127
The effects of bisphosphonates on the resorption cycle of isolated osteoclasts
Selander, K. S., Lehenkari, P. P., & V��n�nen, H. K. (1994) · Calcified Tissue International · doi:10.1007/bf00299317 · Cited by 123
Mechanisms of Bisphosphonate Effects on Osteoclasts, Tumor Cell Growth, and Metastasis
Green, J. R., & Clézardin, P. (2002) · American Journal of Clinical Oncology · doi:10.1097/00000421-200212001-00002 · Cited by 116
Bisphosphonates Induce Apoptosis of Stromal Tumor Cells in Giant Cell Tumor of Bone
Cheng, Y. Y., Huang, L., Lee, K., Xu, J., Zheng, M., & Kumta, S. M. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0120-2 · Cited by 113
Thumbigere‐Math, V., Tu, L. S., Huckabay, S., Dudek, A. Z., Lunos, S. A., Basi, D. L., Hughes, P. J., Leach, J. W., Swenson, K. K., & Gopalakrishnan, R. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182155fcb · Cited by 129
Growth Factor Delivery for Bone Tissue Engineering
Gittens, S. A., & Uludağ, H. (2001) · Journal of drug targeting · doi:10.3109/10611860108998776 · Cited by 115
Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption
Green, J. R., & Rogers, M. J. (2002) · Drug Development Research · doi:10.1002/ddr.10071 · Cited by 100
Boyce, R. W., Paddock, C. L., Gleason, J. R., Sletsema, W. K., & Eriksen, E. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100207 · Cited by 99
Berenson, J. R., Vescio, R. A., Rosen, L. S., VonTeichert, J. M., Woo, M., Swift, R. A., Savage, A., Givant, E., Hupkes, M., Harvey, H. A., et al. (2001) · PubMed · Cited by 102
Ito, M., Amizuka, N., Nakajima, T., & Ozawa, H. (1999) · Bone · doi:10.1016/s8756-3282(99)00197-0 · Cited by 89
Kim, T.-W., Yoshida, Y., Yokoya, K., & Sasaki, T. (1999) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/s0889-5406(99)70290-8 · Cited by 97
Brubaker, K. D., Brown, L. G., Vessella, R. L., & Corey, E. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-15 · Cited by 80
“Zoledronic acid (ZOL) is one of the most potent of the new-generation bisphosphonates (BPs), compounds that inhibit bone lysis and have been used in the treatment of bone diseases and bone metastastatic disease [2-7], and stimulate apoptosis in cancer cells [8-10].”
BackgroundMönkkönen, J., Similä, J., & Rogers, M. J. (1998) · Life Sciences · doi:10.1016/s0024-3205(97)01178-8 · Cited by 80
Räikkönen, J., Crockett, J. C., Rogers, M. J., Mönkkönen, H., Auriola, S. O. K., & Mönkkönen, J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00160.x · Cited by 78
“Bisphosphonates (BPs) are pyrophosphate analogues that concentrate specifically in bone and are highly effective inhibitors of bone resorption (Flanagan and Chambers, 1991; Rogers et al., 2000).”
BackgroundBisphosphonate‐associated osteonecrosis of the jaw: does it occur in children?
Brown, J. J., Ramalingam, L., & Zacharin, M. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03189.x · Cited by 77
Ashokan, A., Gowd, G. S., Somasundaram, V. H., Bhupathi, A., Peethambaran, R., Unni, A. K. K., Palaniswamy, S. S., Nair, S. V., & Koyakutty, M. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.05.077 · Cited by 75
“The high affinity of bisphosphonates (BP) to calcium phosphate is being exploited in the field of diagnostics [54] and therapy [55] of bone diseases.”
BackgroundThe role of bisphosphonates in diseases of childhood
Srivastava, T., & Alon, U. S. (2003) · European Journal of Pediatrics · doi:10.1007/s00431-003-1298-4 · Cited by 65
Rogers, M. J., Xiong, X., Ji, X., Mönkkönen, J., Russell, R. G. G., Williamson, M. P., Ebetino, F. H., & Watts, D. J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012157212793 · Cited by 68
Ullén, A., Lennartsson, L., Harmenberg, U., Hjelm-Eriksson, M., Kälkner, K. M., Lennernäs, B., & Nilsson, S. F. (2005) · Acta Oncologica · doi:10.1080/02841860510029617 · Cited by 66
Potential Anticancer Properties of Bisphosphonates
Neville-Webbe, H. L., Gnant, M., & Coleman, R. E. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.06.008 · Cited by 67
Kim, S.-J., Uehara, H., Yazıcı, S., He, J., Langley, R. R., Mathew, P. F., Fan, D., & Fidler, I. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3601 · Cited by 68
“STI571 + zoledronate + paclitaxel 39 F 12 59 F 15 15 F 6 14 (4-21)”
Hunt, J. A., Flanagan, B. F., McLaughlin, P. J., Strickland, I., & Williams, D. F. (1996) · Journal of Biomedical Materials Research · doi:10.1002/(sici)1097-4636(199605)31:1<139::aid-jbm15>3.0.co;2-i · Cited by 107
Bisphosphonates: From Grandparents to Grandchildren
Srivastava, T., & Alon, U. S. (1999) · Clinical Pediatrics · doi:10.1177/000992289903801201 · Cited by 64
Mitrofan, L. M., Pelkonen, J., & Mönkkönen, J. (2009) · Bone · doi:10.1016/j.bone.2009.08.010 · Cited by 61
“Bisphosphonates (BPs) are pyrophosphate analogs that are highly effective inhibitors of bone resorption [1,2], and thus widely used in the treatment of skeletal diseases associated with high osteoclast activity and accelerated bone turnover, such as osteoporosis [3] and Paget's disease [4].”
Kypreos, K. E., & Sonenshein, G. E. (1998) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19980201)68:2<174::aid-jcb4>3.0.co;2-s · Cited by 15
The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene?
Valenti, M. T., Bertoldo, F., Carbonare, L. D., Azzarello, G., Zenari, S., Zanatta, M., Balducci, E., Vinante, O., & Cascio, V. L. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-49 · Cited by 54
Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption
Sabokbar, A., Fujikawa, Y., Murray, D. W., & Athanasou, N. A. (1998) · Annals of the Rheumatic Diseases · doi:10.1136/ard.57.10.614 · Cited by 56
Cohen, M. H., Dagher, R. N., Griebel, D. J., Ibrahim, A., Martin, A. A., Scher, N. S., Sokol, G. H., Williams, G. A., & Pazdur, R. (2002) · The Oncologist · doi:10.1634/theoncologist.7-5-393 · Cited by 53
Sirisoontorn, I., Hotokezaka, H., Hashimoto, M., Gonzales, C., Luppanapornlarp, S., Darendeliler, M. A., & Yoshida, N. (2012) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/j.ajodo.2011.11.016 · Cited by 53
Muguruma, H., Yano, S., Kakiuchi, S., Uehara, H., Kawatani, M., Osada, H., & Sone, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1335 · Cited by 51
Santini, D., Vincenzi, B., Hannon, R. A., Brown, J. E., Dicuonzo, G., Angeletti, S., Cesa, A. L., Coleman, R. L., Tonini, G., Budillon, A., et al. (2006) · Oncology Reports · doi:10.3892/or.15.5.1351 · Cited by 51
Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone
Sone, S., & Yano, S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9081-z · Cited by 49
“Bisphosphonates are hydrolysis-resistant PP1 derivatives that have a high affinity for bone and inhibit osteoclastic bone resorption [19].”
BackgroundKouloulias, V., Matsopoulos, G. K., Kouvaris, J., Dardoufas, C. E., Bottomley, A., Varela, M., Uzunoglu, N., Antypas, C. E., Metafa, A., Moulopoulos, L. A., et al. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00525-x · Cited by 48
The Role of BMP Signaling in Osteoclast Regulation
Heubel, B. P., & Nohe, A. (2021) · Journal of Developmental Biology · doi:10.3390/jdb9030024 · Cited by 49
Holmes, J. M., Mirams, M., Mackie, E. J., & Whitton, R. C. (2014) · The Veterinary Journal · doi:10.1016/j.tvjl.2014.09.010 · Cited by 47
Zoledronic acid: pharmacologic profile of a potent bisphosphonate
Green, J. R. (2004) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2004.09.069 · Cited by 54
Bramati, A., Girelli, S., Farina, G., Dazzani, M. C., Torri, V., Moretti, A., Piva, S., Dimaiuta, M., & Verde, N. M. L. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0566-x · Cited by 50
Rustemeyer, J., & Bremerich, A. (2009) · Clinical Oral Investigations · doi:10.1007/s00784-009-0294-0 · Cited by 42
Roslinski, D. L., Bhatnagar, K. P., Burrows, A. M., & Smith, T. D. (2000) · The Anatomical Record · doi:10.1002/1097-0185(20000901)260:1<92::aid-ar100>3.0.co;2-# · Cited by 41
Peinado, M. A., Quesada, A., Pedrosa, J. A., Martinez, M., Esteban, F. J., del Moral, M. L., & Peinado, J. M. (1997) · The Anatomical Record · doi:10.1002/(sici)1097-0185(199703)247:3<420::aid-ar14>3.0.co;2-r · Cited by 57
Journal of Bone and Mineral Research
Ott, S. M. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650081329 · Cited by 41
Safety and Efficacy of Intravenous Zoledronic Acid in Paediatric Osteoporosis
Brown, J. J., & Zacharin, M. (2009) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2009.22.1.55 · Cited by 41
Paoletti, F., Mocali, A., & Tombaccini, D. (1997) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199707)172:1<63::aid-jcp7>3.0.co;2-b · Cited by 29
Self-citationChoi, J., Baek, S., Lee, J., & Chang, Y.-I. (2010) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/j.ajodo.2010.01.031 · Cited by 50
Osteoclast recruitment in mice is stimulated by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate.
Marshall, M. J., Holt, I., & John Davie, M. W. (1993) · Calcified Tissue International · doi:10.1007/bf00675622 · Cited by 37
Effect of alendronate sodium on tooth movement in ovariectomized rats
Salazar, M., Hernandes, L., Ramos, A. L., de Oliveira, B., Micheletti, K. R., Paranhos, L. R., de Mendonça, M. R., & Cuoghi, O. A. (2015) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2015.02.003 · Cited by 34
Pandey, R., Quinn, J. M. W., Sabokbar, A., & Athanasou, N. A. (1996) · Acta Orthopaedica Scandinavica · doi:10.3109/17453679608994677 · Cited by 36
Westin, J. R., Thompson, M. A., Cataldo, V. D., Fayad, L., Fowler, N. H., Fanale, M. A., Neelapu, S., Samaniego, F., Romaguera, J. E., Shah, J. J., et al. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.11.002 · Cited by 34
Fuller, K., Thong, J. T. L., Breton, B. C., & Chambers, T. J. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090104 · Cited by 33
Self-citationBisphosphonates and oral pathology I. General and preventive aspects.
Fernández, N. P., Estefanía‐Fresco, R., & Urízar, J. M. A. (2006) · PubMed · Cited by 32
Corso, A., Ferretti, E., & Lazzarino, M. (2005) · Hematology · doi:10.1080/10245330500094714 · Cited by 33
“[37] Flanagan AM, Chambers TJ.”
BackgroundYu, X., Schøller, J., & Foged, N. T. (1996) · Bone · doi:10.1016/s8756-3282(96)00184-6 · Cited by 36
Short-Term Intravenous Bisphosphonates in Prevention of Postmenopausal Bone Loss
Heikkinen, J. E., Selander, K. S., Laitinen, K., Arnala, I., & Väänänen, H. K. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.1.103 · Cited by 31
Avcu, F., Ural, A. U., Yılmaz, M. İ., Özcan, A., İde, T., Kurt, B., & Yalçın, A. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00427.x · Cited by 29
Landgraf, M., Lahr, C. A., Sánchez‐Herrero, A., Meinert, C., Shokoohmand, A., Pollock, P. M., Hutmacher, D. W., Shafiee, A., & McGovern, J. (2019) · Bone Research · doi:10.1038/s41413-019-0072-9 · Cited by 29
Bisphosphonate acts on osteoclasts independent of ruffled borders in osteosclerotic (oc/oc) mice
Ito, M., Amizuka, N., Nakajima, T., & Ozawa, H. (2001) · Bone · doi:10.1016/s8756-3282(01)00429-x · Cited by 28
Duplat, D., Gallet, M., Berland, S., Marie, A., Dubost, L., Marthe Rousseau, A., Kamel, S., Milet, C., Brazier, M., Lopez, É., et al. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.07.036 · Cited by 28
Hyvönen, P. M., Karhi, T., Kosma, V., Liimola‐Luoma, L., & Hanhijärvi, H. (1994) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1994.tb00379.x · Cited by 28
MACFARLANE, D. J., Durrant, S., Bartlett, M. L., Allison, R., & Morton, A. J. (2002) · Nuclear Medicine Communications · doi:10.1097/00006231-200211000-00010 · Cited by 23
Collagen Cross-Linking and Metabolism
Robins, S. P., & Brady, J. D. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00035-5 · Cited by 28
Clodronate improves lameness in horses without changing bone turnover markers
Mitchell, A. A., Wright, G., Sampson, S. N., Martin, M., Cummings, K. J., Gaddy, D., & Watts, A. E. (2018) · Equine Veterinary Journal · doi:10.1111/evj.13011 · Cited by 22
Piper, K., BOYDE, A., & Jones, S. J. (1994) · Calcified Tissue International · doi:10.1007/bf00316291 · Cited by 24
Lysosomal-Mitochondrial Axis in Zoledronic Acid-induced Apoptosis in Human Follicular Lymphoma Cells
Mitrofan, L. M., Castells, F. B., Pelkonen, J., & Mönkkönen, J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.038935 · Cited by 25
Jacobs, C., Walter, C., Ziebart, T., Dirks, I., Schramm, S., Grimm, S., Krieger, E., & Wehrbein, H. (2014) · Clinical Oral Investigations · doi:10.1007/s00784-014-1284-4 · Cited by 25
“Bisphosphonates are internalized in osteoclasts, inducing their apoptosis and eventually inhibiting bone resorption [8, 9].”
Atahan, L., Yıldız, F., Cengiz, M., Kaplan, B., Özkan, M., Yazıcı, G., Gündoğ, M., Haydaroğlu, A., Korcum, A. F., Şengöz, M., et al. (2009) · Supportive Care in Cancer · doi:10.1007/s00520-009-0663-x · Cited by 19
Skeletal Response to Clodronate in Prostate Cancer with Bone Metastases
Fernández-Conde, M., Alcóver, J., Aaron, J. E., Ordï, J., & Carretero, P. (1997) · American Journal of Clinical Oncology · doi:10.1097/00000421-199710000-00007 · Cited by 19
Nowak, S. M., Sacco, R., Mitchell, F. L., Patel, V., & Gurzawska, K. (2024) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2024.01.007 · Cited by 24
Pharmacokinetics, pharmacodynamics, and safety of zoledronic acid in horses
Nieto, J. E., Maher, O., Stanley, S. D., Knych, H. K. D., & Snyder, J. R. (2013) · American Journal of Veterinary Research · doi:10.2460/ajvr.74.4.550 · Cited by 18
Mayahara, M., & Sasaki, T. (2003) · The Anatomical Record Part A Discoveries in Molecular Cellular and Evolutionary Biology · doi:10.1002/ar.a.10092 · Cited by 22
Kuriyama, S., Tomonari, H., Nakayama, M., Kawaguchi, Y., & Sakai, O. (1998) · Blood Purification · doi:10.1159/000014312 · Cited by 18
Metadata
- Authors
- Flanagan, A. M., & Chambers, T. J.
- Affiliations
- St George's Hospital (GB)
- St George's, University of London (GB)
- Venue
- Calcified Tissue International
- Published
- 1991-11
- Volume
- 49
- Issue
- 6
- Pages
- 407-415
- ISSN
- 0171-967X (ISSN-L)
- 1432-0827
- OpenAlex
- W2004135633
- Cited by
- 171
- References
- 39
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 6 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 3 · 2016: 1 · 2015: 4 · 2014: 5 · 2013: 4 · 2012: 2
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Calcified Tissue International (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- bisphosphonates, bone resorption inhibition, osteoclasts, pyrophosphate analogues, calcitonin, osteoblasts
- MeSH terms
- Pamidronate, Animals, Bone and Bones, Bone Marrow Cells, Bone Resorption, Calcitonin, Cells, Cultured, Clodronic Acid, Diphosphonates, Microscopy, Electron, Osteoclasts, Rats, Inbred Strains, Culture Techniques, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.